PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-No auction for Vectura as Carlyle declares $1.3 bln takeover bid final

Tue, 10th Aug 2021 17:02

(Recasts, adds detail, background)

By Yadarisa Shabong

Aug 10 (Reuters) - The takeover battle between tobacco giant
Philip Morris and private equity firm Carlyle for
inhaled treatments maker Vectura will not be heading to
the auction ring on Wednesday after Carlyle said it will not
raise its bid.

U.S.-based Carlyle on Tuesday declared final its 155 pence
per Vectura share offer, which it sweetened last week to value
the British company at about 958 million pounds ($1.33 billion).
The proposal is below an increased 165 pence bid from Philip
Morris on Sunday.

Britain's takeover regulator on Monday had intervened in the
battle, saying that it would enter a rare head-to-head auction https://www.reuters.com/world/uk/britains-takeover-regulator-intervenes-battle-drugmaker-vectura-2021-08-09
if the bidders do not make final bids by Tuesday 1600 GMT (1700
BST).

Only a handful of British takeover fights have gone to
auction, with the highest profile in recent years being the
battle in 2018 for pay-television group Sky when Comcast
emerged as the winner of a single-day three round
blind auction.

London-listed shares of Vectura closed at 163.4 pence on
Tuesday after hitting a more than five-year high of 176 pence
earlier in the session. They have gained 33% in value since
Carlyle's first offer in May.

Vectura has been the target of several approaches since May
from the U.S.-based groups, which are eyeing the drugmaker's
expertise with inhalable formulations and device designs for
respiratory therapies for illnesses such as asthma.

The London-listed company had voiced its support for the
Carlyle offer last week, saying that it may be better positioned
under the ownership of the private equity firm, while noting the
uncertainties that could arise for its stakeholders as a result
of being owned by the Marlboro cigarette-maker.

However, Vectura withdrew its backing and also withheld
support for the higher offer from Philip Morris following the
intervention from the Takeover Panel.

Vectura did not immediately respond to a request for
comment.

A deal with either one of the U.S. companies would require
shareholder approval.
($1 = 0.7229 pounds)

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Shounak
Dasgupta and Lisa Shumaker)

More News
19 Mar 2021 09:46

BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson

BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson

Read more
18 Mar 2021 10:36

Vectura shares rise on swing to profit, GBP115 million special payout

Vectura shares rise on swing to profit, GBP115 million special payout

Read more
18 Mar 2021 07:43

Royalty income, litigation win see Vectura beat expectations

(Sharecast News) - Vectura reported a 6.9% improvement in its total revenue on Thursday, to £190.6m, driven by development services and a surge in income from royalties.

Read more
11 Mar 2021 16:13

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
5 Mar 2021 12:29

Vectura delays results because of KPMG staff shortage

(Sharecast News) - Vectura delayed the publication of its annual results after KPMG asked for more time to audit the accounts because of a staff shortage caused by Covid-19.

Read more
2 Mar 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
22 Jan 2021 09:32

LONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec

LONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec

Read more
12 Jan 2021 10:13

Vectura Forecasts 2020 Earnings To Top Board Expectations

Vectura Forecasts 2020 Earnings To Top Board Expectations

Read more
12 Jan 2021 08:16

Vectura reports 'strong' operational performance in 2020

(Sharecast News) - Inhaled medicines-focussed pharmaceutical company Vectura Group updated the market on its trading on Tuesday, saying it expected revenue and adjusted EBITDA for 2020 to be ahead of board expectations, following the fourth quarter approval of VR315 (US), or generic 'Advair', alongside Hikma.

Read more
30 Dec 2020 19:10

UK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle

UK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle

Read more
29 Dec 2020 12:04

Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation

Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation

Read more
29 Dec 2020 10:04

Glaxo not seeking re-hearing in Ellipta litigation, says Vectura

(Sharecast News) - Vectura said on Tuesday that GlaxoSmithKline has not sought to petition the US Court of Appeals for a re-hearing in the companies' ongoing litigation over GSK's Ellipta inhalers.

Read more
18 Dec 2020 17:08

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 10:45

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.